Customers of genetic knowledge outfit 23andMe could also be at larger threat than they notice, suggests a New York Times story that argues the corporate’s woes could possibly be short-lived in comparison with the longer-term threats probably dealing with these roughly 15 million folks if 23andMe can’t proceed as a going concern.
Certainly, with every passing day, the hope of founder and CEO Anne Wojcicki to show round 23andMe appears additional out of attain. The firm, valued at $6 billion when it went public in 2021, is now valued at $150 million. It’s poised to be delisted subsequent month. Press tales aren’t serving to. (Would you purchase a equipment?)
The firm says it stays dedicated to “follow laws that regulate the data we collect,” but when in some unspecified time in the future very quickly it may well’t, that’s worrisome, says a Yale biomedical professor who notes to the Times that hacked bank cards will be changed; a genome can not. Meanwhile, he says, the tech that analyzes genomes is advancing. Chances are it is going to grow to be extra revealing, too.
